CYP2C19

Inflammation-driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients

Voriconazole after hematopoietic stem cell transplantation — inflammation-driven phenoconversion

Paradoxical myocardial infarction risk with dual antiplatelet therapy in East Asian ischaemic stroke: a nationwide real-world cohort study and pharmacogenomic risk prediction model

Secondary ischemic stroke prevention — dual antiplatelet therapy and *CYP2C19* in East Asian populations

Pharmacogenetic phenoconversion modeling of drug-drug-gene interactions on CYP2C19 activity: effects of comedication by genotype on escitalopram concentrations

Escitalopram — modeling of drug-drug-gene interactions on *CYP2C19* activity

Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug-Eluting Stent Implantation.

Acute coronary syndrome on clopidogrel — CYP2C19 genotype prognostic effect differs by sex

CRISPR-Based Assay for Point-of-Care Pharmacogenetic CYP2C19 Genotyping

Point-of-care *CYP2C19* genotyping — CRISPR assay

High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism Among Patients With Gastroesophageal Reflux Disease.

Gastroesophageal reflux disease — PPI failure, CYP2C19 rapid/ultrarapid metabolizer prevalence

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention.

CYP2C19 phenoconversion under drug inhibitors after percutaneous coronary intervention

Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome: A Combined Analysis

Acute coronary syndrome (ACS) — MACE risk under clopidogrel

Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects.

Selective serotonin reuptake inhibitor side effects

Exposure to CYP2C19-metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing.

Ischaemic stroke — exposure to CYP2C19 substrates

The association of ABCB1, CYP2C19 and CYP2C9 combined activity with clopidogrel resistance in patients with recurrent ischemic stroke

Clopidogrel resistance — recurrent ischemic stroke

Evaluation of a pantoprazole and 4-desmethylpantoprazole-sulfate metabolic ratio as a novel CYP2C19 phenotyping method

CYP2C19 functional phenotyping — validation of pantoprazole/4-desmethylpantoprazole-sulfate metabolic ratio as phenotyping probe

Genotype influences antidepressant discontinuation in a pre-emptive pharmacogenetic testing population.

Depression / Anxiety

CYP2C19 genotype-guided antiplatelet therapy to prevent thromboembolic events after stent-assisted coil embolization of unruptured intracranial aneurysms: a retrospective cohort study.

Unruptured intracranial aneurysm treated by stent-assisted coil embolization

Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature.

Under-implementation of clopidogrel pharmacogenetics in cardiology

Pharmacogenomic Profiling of Voriconazole Enables Predicting Its Toxicity in Pediatric Leukemia and Hematopoietic Stem Cell Transplant Recipients.

Voriconazole toxicity in pediatric leukemia and HSCT — prediction by CYP2C19 genotype

Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort study

Major depressive disorder (MDD) — antidepressant adverse drug reactions

Identification and functional characterization of 11 novel CYP2C19 variants in the Chinese Han population

CYP2C19 metabolic variability — new alleles in Chinese Han population

Challenges and prospects of CYP2C19 genotype-guided clopidogrel therapy from the perspective of precision medicine

Post-PCI antiplatelet therapy — debate on CYP2C19 genotyping generalization

Pharmacogenomic landscape in Thailand: Array-based profiling and EMR-linked medication exposure

Pharmacogenomic implementation in a Thai population

Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI.

Dual antiplatelet therapy after percutaneous coronary intervention

A primary care pharmacogenetic precision medicine pilot based on specific Māori tribal ethical frameworks and principles

Primary care pharmacogenetics — Māori tribal ethical framework

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Cardiovascular diseases / pharmacogenomics

Optimizing P2Y12 Inhibitor Therapy in Post-PCI Patients Through Genotype-Guided Strategies: A Systematic Review and Meta-Analysis.

Post-PCI — CYP2C19 genotype-guided P2Y12 inhibitor therapy optimization

Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy.

Invasive fungal infections — voriconazole

Pre-emptive CYP2C19 genotyping and voriconazole exposure in pediatric hematology patients at risk of aspergillosis: an exploratory randomized pilot study with a cost-consequence analysis.

Voriconazole exposure in paediatric haematology

CYP2C19 c.681G>A Is not in Complete Linkage Disequilibrium With c.332-23A>G: Implications for Pharmacogenetic Testing

CYP2C19 genotype interpretation

Integrating Clinical Evidence with PBPK Modeling to Assess PPI-Clopidogrel-CYP2C19 Interactions in Chinese ACS Patients.

Acute coronary syndrome — PPI-clopidogrel interaction